271K oncology patents: CORE tier for business intelligence, PRO tier for data science.
FDA Approvals · Clinical Trials · Citation Networks · ML Features · Predictive Scoring.
Note: A curated subset of the USPTO archive focused on cancer and oncology.
Healthcare & Biotech
271,244 patents
Weekly (Last: 2025-11-27)
Target healthcare innovation and oncology pipelines
Oncology IP Pulse delivers 271,244 cancer-focused patents (1911–2016) in two tiers: CORE for pharma/biotech business teams with ~55 essential columns, and PRO for data scientists with 191 columns including 60+ pre-engineered ML features.
Both tiers include FDA approval links (2,675 patents), clinical trial connections (23,008 patents), patent family clustering, and assignee portfolio intelligence. The PRO tier adds advanced citation network analytics, temporal evolution indicators, diversity metrics, commercial validation signals, quality/risk assessments, and composite scores for predictive modeling.
Oncology IP Pulse delivers deep intelligence on cancer innovation. The roadmap integrates clinical trials and real-world drug safety data.
269K curated patents (1911–2016) specifically focused on cancer research.
1.12M citation edges mapping the flow of innovation and prior art influence.
7.2K patents directly linked to National Institutes of Health funding grants.
1.1K patents mapped to FDA Orange Book approvals and regulatory filings.
Granular tagging for specific cancer types, mechanisms, and therapies.
Patent velocity, citation impact scores, R&D intensity indicators.
Direct mapping to ClinicalTrials.gov studies and outcomes.
Integration with FDA drug labels for indications and warnings.
Correlation with FAERS data for safety signal detection.
Expansion to EPO/WIPO cancer patents for worldwide coverage.
Choose between business intelligence (CORE) or data science (PRO)
Essential commercial intelligence for pharma/biotech business teams.
Full ML features for data scientists and quant researchers.